Despite this high frequency, KRAS mutations have a very limited and uncertain role as prognostic or predictive biomarkers in patients with NSCLC, and precision medicine does not appear to be an adequate approach for this subgroup of patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.